Synthego says the $110 million in Series C financing it raised this week will enable it to proceed with ambitious expansion plans that include extending its full stack genome engineering platform, growing its CRISPRevolution and Engineered Cells product lines, and increasing its global footprint in Europe and Asia.
Through these and other initiatives, the provider of genome engineering products and services expects to grow its workforce beyond the current 130 staffers.
“We’ve been doubling every year, and we expect to continue to double every year,” Synthego COO Ted Tisch told GEN this week. “We are very particular . . .